[BMRN] BioMarin Pharmaceutical Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 85.66 Change: 2.12 (2.54%)
Ext. hours: Change: 0 (0%)

chart BMRN

Refresh chart

Strongest Trends Summary For BMRN

BMRN is in the medium-term down -12% below S&P in 3 months. In the long-term up 92% above S&P in 24 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Ph

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.02 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 5.98% Sales Growth - Q/Q-11.95% P/E-86.75
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-4.46% ROE-6.74% ROI-5.17%
Current Ratio4.98 Quick Ratio4.25 Long Term Debt/Equity0.54 Debt Ratio0.13
Gross Margin82.59% Operating Margin-16.48% Net Profit Margin-20.35% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities914.79 M Cash From Investing Activities-750.87 M Cash From Operating Activities-137.81 M Gross Profit170.45 M
Net Profit-67.5 M Operating Profit-66.02 M Total Assets3.66 B Total Current Assets1.52 B
Total Current Liabilities305.51 M Total Debt655.49 M Total Liabilities1.23 B Total Revenue203.26 M
Technical Data
High 52 week106.07 Low 52 week77.67 Last close91.36 Last change3.97%
RSI33.47 Average true range3.1 Beta1.08 Volume685.95 K
Simple moving average 20 days-2.92% Simple moving average 50 days-0.47% Simple moving average 200 days-4.47%
Performance Data
Performance Week-2.8% Performance Month-1.42% Performance Quart-0.12% Performance Half-10.02%
Performance Year1.53% Performance Year-to-date7.29% Volatility daily1.91% Volatility weekly4.28%
Volatility monthly8.76% Volatility yearly30.36% Relative Volume211.9% Average Volume968.77 K
New High New Low

News

2019-04-18 10:33:02 | Earnings Preview: BioMarin Pharmaceutical BMRN Q1 Earnings Expected to Decline

2019-04-17 11:18:00 | Forbes Names BioMarin 4th Best Midsize Employer in America

2019-04-17 10:06:46 | As Nasdaq 100 hits record, Apple and Intel could still be buys, says expert

2019-04-16 10:51:02 | New Strong Sell Stocks for April 16th

2019-04-12 07:06:03 | 8 Stocks May Jump on Takeovers as Market Nears Peak

2019-04-10 07:25:00 | FireEye joins major Bay Area employers like Facebook, Netflix, Google, Microsoft and Salesforce in paying a typical worker more than $150,000 per year

2019-04-09 10:48:29 | See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

2019-04-03 08:13:00 | Does Sangamo Have the Best Gene Therapy Program Now?

2019-04-02 09:56:34 | Elon Musk’s CEO pay-to-worker ratio is the highest ever recorded — how it compares at other tech companies

2019-04-02 08:30:00 | BioMarin to Host First Quarter 2019 Financial Results Conference Call and Webcast on Thursday, April 25 at 4:30pm ET

2019-03-31 19:57:35 | Here is What Hedge Funds Think About BioMarin Pharmaceutical Inc. NASDAQ:BMRN

2019-03-29 11:15:03 | New Strong Sell Stocks for March 29th

2019-03-28 08:04:41 | See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

2019-03-27 10:03:02 | New Strong Sell Stocks for March 27th

2019-03-27 09:15:01 | S&P Fights Past Growth Concerns to Reclaim 2800

2019-03-25 10:10:00 | 3 Stocks to Buy Ahead of the Next Market Crash

2019-03-23 09:30:01 | Why Is BioMarin BMRN Down 0.9% Since Last Earnings Report?

2019-03-22 15:01:05 | Analysts Are Mostly Positive on BioMarin Pharmaceutical in March

2019-03-20 16:55:16 | S.F. hotel demand bubbles over, spilling out into the rest of the Bay Area

2019-03-18 10:47:02 | New Strong Sell Stocks for March 18th

2019-03-13 09:15:01 | Boeing Keeps Dow from Joining Rally

2019-03-12 10:26:39 | See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

2019-03-08 11:09:29 | Did BioMarin Pharmaceutical Inc. NASDAQ:BMRN Insiders Sell Shares?

2019-03-07 07:50:12 | New Strong Sell Stocks for March 7th

2019-03-06 08:30:00 | BioMarin to Participate in Cowen and Company 39th Annual Health Care Conference on March 12 in Boston

2019-03-05 07:30:00 | The $200K Club: Broadcom joins these Bay Area tech companies paying a typical employee top dollar

2019-03-01 21:29:00 | Why Big Pharma Is Diving Into Gene Therapy

2019-03-01 07:28:00 | BioMarin Receives Positive CHMP Opinion in Europe for Palynziq® pegvaliase Injection for Treatment of Patients with Phenylketonuria PKU Aged 16 and Older

2019-02-28 10:54:03 | Sarepta SRPT Q4 Earnings Lag Estimates, Exondys 51 Sales Up

2019-02-26 15:26:00 | BioMarin Revenue Slips, but Big Picture Looks Dandy

2019-02-26 07:30:00 | Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures

2019-02-26 07:19:00 | 2 More Gene Therapy Stocks on Big Pharma's Buyout Radar

2019-02-25 15:12:37 | Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

2019-02-25 09:21:00 | MarketPulse: Roche's Bumper Deal for Spark Therapeutics Boosts Healthcare Stocks

2019-02-24 10:46:09 | Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers

2019-02-23 07:54:07 | Edited Transcript of BMRN earnings conference call or presentation 21-Feb-19 9:30pm GMT

2019-02-22 16:21:44 | Can This Biotech Stock Redeem Its Sales Lag With A Strong Gene Therapy?

2019-02-22 10:12:47 | BioMarin Pharmaceutical Inc. BMRN Q4 2018 Earnings Conference Call Transcript

2019-02-22 09:23:02 | BioMarin BMRN Q4 Earnings & Sales Miss, Shares Decline

2019-02-22 08:50:41 | The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data

2019-02-21 17:09:28 | BioMarin: 4Q Earnings Snapshot

2019-02-21 16:05:00 | BioMarin Announces Full Year and Fourth Quarter 2018 Results

2019-02-17 08:14:53 | FOMC minutes, Walmart earnings – What to know in the week ahead

2019-02-15 07:30:00 | The typical Facebook employee earns double Silicon Valley's median household income. How 50+ big tech employers compare

2019-02-14 10:31:03 | BioMarin Pharmaceutical BMRN Reports Next Week: Wall Street Expects Earnings Growth

2019-02-13 08:25:00 | Market Trends Toward New Normal in Brighthouse Financial, BioMarin Pharmaceutical, EZCORP, Assembly Biosciences, A-Mark Precious Metals, and American Public Education — Emerging Consolidated Expectations, Analyst Ratings

2019-02-09 08:16:00 | Is Sangamo's Gene-Editing Approach a Bust?

2019-02-08 09:17:26 | The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs

2019-02-08 08:02:21 | See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

2019-02-07 16:28:00 | BioMarin Announces Ongoing Study Demonstrates Durable Treatment Benefit from Brineura® cerliponase alfa for 3 Years